Shareholder Update October 2014

7 October 2014

In this Issue:

› Encouraging clinical data for DEP™ docetaxel

› VivaGel® condom approved for sale in Australia – Launch imminent

› VivaGel® for BV: SPA agreement for Phase 3 and commercialisation activities for Symptomatic Relief

› Starpharma completes $18M Placement; launches $5M SPP

› Dendrimer-enhanced agrochemicals

› Full Year 2014 annual financial results

 

Download: Shareholder Update October 2014 (pdf file, 1MB)


About Starpharma

This document contains Forward Looking Statements

For Further Information


© Starpharma Holdings Limited 2017